Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis

Giuseppe Di Lorenzo, Carlo Buonerba, Piera Federico, Sisto Perdonà, Michele Aieta, Pasquale Rescigno, Carmine D'Aniello, Livio Puglia, Antonella Petremolo, Matteo Ferro, Alfredo Marinelli, Giovannella Palmieri, Guru Sonpavde, Vincenzo Mirone, Sabino De Placido

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: • To investigate the activity and toxicity of 5-fluorouracil (5-FU) as a first-line treatment in metastatic squamous cell carcinoma of the penis (SCCP). METHODS: • The medical records of 78 patients with SCCP treated between January 2000 and June 2011 at the four participating centres were reviewed. • Data regarding patients treated with first-line 5-FU were extracted. • Patients were included in the study if radiological reports were available for determination of response and progression-free survival (PFS) according to response evaluation criteria in solid tumours (RECIST) 1.1. RESULTS: • Between January 2000 and June 2011, 25 patients were treated with i.v. cisplatin on day 1 followed by 5-FU as a continuous 24-h infusion for 4 days every 3 weeks until disease progression or unacceptable toxicity. Partial responses and stable disease were observed in eight (32%) and 10 (40%) patients, respectively, with a disease control rate of 72%. • Severe neutropenia was the most important grade 3 - 4 side effect observed, occurring in 20% of patients. • The median (interquartile range [ IQR ] ) PFS was 20 (11 - 20) weeks and the median (IQR) overall survival (OS) was 8 (7 - 12) months. CONCLUSION: • 5-FU is associated with a moderate response rate and is well tolerated in patients with metastatic SCCP.

Original languageEnglish
JournalBJU International
Issue number11 B
Publication statusPublished - Dec 2012


  • Advanced penile cancer
  • Chemotherapy
  • Cisplatin-based regimen

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis'. Together they form a unique fingerprint.

Cite this